Literature DB >> 11445192

Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction.

S Lamarque1, K Taghzouti, H Simon.   

Abstract

Cannabis sativa preparations are some of the most widely used illicit recreational drugs. In addition to their direct addictive potential, cannabinoids may influence the sensitivity to other drugs. The aim of the present study was to determine if a cross-sensitization between Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other drugs (amphetamine and heroin) could be demonstrated. We examined the effects of a chronic treatment with Delta(9)-THC (0.6, 3 and 15mg/kg, ip) on the locomotor response to amphetamine (1mg/kg, ip) and heroin (1mg/kg, ip). Chronic treatment with Delta(9)-THC resulted in tolerance to the initial hypothermic and anorexic effects. Pre-treatment with Delta(9)-THC increased the locomotor responses to amphetamine and heroin. This cross-sensitization was time-dependent as it was observed three days after the last injection of Delta(9)-THC for amphetamine, and a relatively long time after the end of chronic treatment (41 days) for heroin. Moreover, the enhanced response to amphetamine or heroin was noted in some individuals only: the high-responder rats (HR). These animals have previously been shown to be vulnerable to drug taking behaviors. It is hypothesised that repeated use of Cannabis derivates may facilitate progression to the consumption of other illicit drugs in vulnerable individuals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445192     DOI: 10.1016/s0028-3908(01)00039-9

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

1.  Understanding Addiction Using Animal Models.

Authors:  Brittany N Kuhn; Peter W Kalivas; Ana-Clara Bobadilla
Journal:  Front Behav Neurosci       Date:  2019-11-29       Impact factor: 3.558

Review 2.  Stimulant-induced psychosis and schizophrenia: the role of sensitization.

Authors:  Hiroshi Ujike
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

3.  Effect of ΔFosB overexpression on opioid and cannabinoid receptor-mediated signaling in the nucleus accumbens.

Authors:  Laura J Sim-Selley; Michael P Cassidy; Antonino Sparta; Venetia Zachariou; Eric J Nestler; Dana E Selley
Journal:  Neuropharmacology       Date:  2011-09-03       Impact factor: 5.250

4.  Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse Forebrain.

Authors:  Matthew F Lazenka; Aaron J Tomarchio; Aron H Lichtman; Paul Greengard; Marc Flajolet; Dana E Selley; Laura J Sim-Selley
Journal:  J Pharmacol Exp Ther       Date:  2015-06-22       Impact factor: 4.030

Review 5.  Drug addiction.

Authors:  Zuzana Justinova; Leigh V Panlilio; Steven R Goldberg
Journal:  Curr Top Behav Neurosci       Date:  2009

6.  Previous exposure to delta9-tetrahydrocannibinol enhances locomotor responding to but not self-administration of amphetamine.

Authors:  James J Cortright; Daniel S Lorrain; Jeff A Beeler; Wei-Jen Tang; Paul Vezina
Journal:  J Pharmacol Exp Ther       Date:  2011-03-09       Impact factor: 4.030

7.  The reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in cannabis users.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Behav Pharmacol       Date:  2010-02       Impact factor: 2.293

8.  Abnormal striatal circuitry and intensified novelty seeking among adolescents who abuse methamphetamine and cannabis.

Authors:  John C Churchwell; Paul D Carey; Helen L Ferrett; Dan J Stein; Deborah A Yurgelun-Todd
Journal:  Dev Neurosci       Date:  2012-09-13       Impact factor: 2.984

Review 9.  Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence.

Authors:  Gianluigi Tanda
Journal:  Pharmacol Res       Date:  2007-09-11       Impact factor: 7.658

Review 10.  Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data.

Authors:  Gianluigi Tanda; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-06-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.